We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

61 hedge funds and large institutions have $165M invested in Protagonist Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more capital invested

Capital invested by funds: $93.6M → $165M (+$71.3M)

0.66% more ownership

Funds ownership: 65.7% → 66.36% (+0.66%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

12% less funds holding

Funds holding: 69 → 61 (-8)

23% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 26

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
20
Reduced
26
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$11.5M
2
BI
BVF Inc
California
+$10.3M
3
Millennium Management
Millennium Management
New York
+$6.93M
4
Jennison Associates
Jennison Associates
New York
+$3.01M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.38M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$4.23M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.36M
3
CAM
Cormorant Asset Management
Massachusetts
-$2.57M
4
AIM
Alambic Investment Management
California
-$1.45M
5
First Manhattan
First Manhattan
New York
-$861K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
26
Alambic Investment Management
California
$670K -$1.45M -168,925 -72%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$651K – – –
AG
28
Algert Global
California
$458K -$64K -7,430 -14%
MIM
29
Monashee Investment Management
Massachusetts
$442K – – –
Goldman Sachs
30
Goldman Sachs
New York
$405K -$374K -43,495 -52%
Squarepoint
31
Squarepoint
New York
$372K -$106K -12,357 -25%
Citadel Advisors
32
Citadel Advisors
Florida
$368K -$823K -95,644 -73%
FIM
33
Freedom Investment Management
Connecticut
$355K +$18.6K +2,166 +6%
Northern Trust
34
Northern Trust
Illinois
$304K -$4.75K -552 -2%
TI
35
Trexquant Investment
Connecticut
$304K +$255K +29,580 New
Walleye Trading
36
Walleye Trading
New York
$284K +$45.1K +5,243 +23%
FSA
37
Franklin Street Advisors
North Carolina
$278K -$2.58K -300 -1%
Jacobs Levy Equity Management
38
Jacobs Levy Equity Management
New Jersey
$273K +$228K +26,500 New
Morgan Stanley
39
Morgan Stanley
New York
$233K -$198K -23,043 -50%
ECM
40
Element Capital Management
New York
$202K -$302K -35,054 -64%
BCM
41
BlueCrest Capital Management
Jersey
$201K -$411K -47,778 -71%
PPA
42
Parametric Portfolio Associates
Washington
$199K -$32.5K -3,775 -16%
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$170K – – –
State Street
44
State Street
Massachusetts
$151K +$2.25K +262 +2%
Bank of America
45
Bank of America
North Carolina
$140K -$65.6K -7,617 -36%
Wells Fargo
46
Wells Fargo
California
$130K -$5.2K -604 -5%
ARTA
47
A.R.T. Advisors
New York
$121K -$573K -66,547 -85%
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$115K -$336K -39,066 -78%
UBS Group
49
UBS Group
Switzerland
$73K -$292K -33,946 -83%
Macquarie Group
50
Macquarie Group
Australia
$66K -$57.7K -6,700 -51%
1
2
3 4

PTGX Hedge Fund Activity: Q3 2018 in Review

61 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2018, worth a combined $165M — up 76% from $93.6M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PTGX and 8 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 20 added.

The largest buyer was Farallon Capital Management, adding an estimated $11.5M. The largest seller was Great Point Partners, cutting an estimated $4.23M.

  • 61 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2018, down from 69 in Q2 2018.
  • Funds reported $165M of Protagonist Therapeutics stock for Q3 2018, up 76% quarter-over-quarter.
  • 8 funds opened new Protagonist Therapeutics positions in Q3 2018 and 16 closed out, a net change of -8 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2018 was Farallon Capital Management, an estimated $11.5M added.
  • The largest Protagonist Therapeutics seller in Q3 2018 was Great Point Partners, an estimated $4.23M sold.

Based on aggregated 13F filings for Q3 2018.